Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL - Brown, J.R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Hillmen, Peter (St James Institute of Oncology) ; O'Brien, S. (MD Anderson Cancer Center) ; Barrientos, J.C. (Hofstra Northwell School of Medicine) ; Reddy, N.M. (Vanderbilt-Ingram Cancer Center) ; Coutre, S.E. (Stanford University) ; Tam, Constantine S (Peter MacCallum Cancer Centre. St Vincent's Hospital) ; Mulligan, S.P. (Royal North Shore Hospital) ; Jaeger, U. (Medical University of Vienna) ; Barr, P.M. (University of Rochester Cancer Center) ; Furman, R.R. (New York Presbyterian Hospital) ; Kipps, Thomas J (UCSD Moores Cancer Center) ; Cymbalista, F. (Hôpital Avicenne) ; Thornton, P. (Beaumont Hospital (Dublín, Irlanda)) ; Caligaris-Cappio, F. (Universita Vita-Salute San Raffaele) ; Delgado, J. (Hospital Clínic i Provincial de Barcelona) ; Montillo, M. (Niguarda Hospital) ; DeVos, S. (David Geffen School of Medicine at UCLA) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Pagel, J.M. (Swedish Cancer Institute) ; Munir, Talha (St James Institute of Oncology) ; Burger, Jan A (MD Anderson Cancer Center) ; Chung, D. (Pharmacyclics LLC. AbbVie Company) ; Lin, J. (Pharmacyclics LLC. AbbVie Company) ; Gau, L. (Pharmacyclics LLC. AbbVie Company) ; Chang, B. (Pharmacyclics LLC. AbbVie Company) ; Cole, G. (Pharmacyclics LLC. AbbVie Company) ; Hsu, E. (Pharmacyclics LLC. AbbVie Company) ; James, D.F. (Pharmacyclics LLC. AbbVie Company) ; Byrd, J.C. (Ohio State University) ; Universitat Autònoma de Barcelona